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Abstract: Over the last decades, there has been an impressive progress in our understanding of
coeliac disease pathogenesis and it has become clear that the disorder is the final result of complex
interactions of environmental, genetic, and immunological factors. Coeliac disease is now considered
a prototype of T-cell-mediated disease characterized by loss of tolerance to dietary gluten and the
targeted killing of enterocytes by T-cell receptor αβ intraepithelial lymphocytes. Accumulating
evidence, however, indicates that the induction of a gluten-specific T helper-1 response must be
preceded by the activation of the innate immune system. Mast cells are key players of the innate
immune response and contribute to the pathogenesis of a multitude of diseases. Here, we review the
results of studies aimed at investigating the role of mast cells in the pathogenesis of coeliac disease,
showing that these cells increase in number during the progression of the disease and contribute to
define a pro-inflammatory microenvironment.
Keywords: mast cells; coeliac disease; gliadin immunology; p31-43 fragment; 33-mer peptide;
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1. Introduction
Coeliac disease (CD) is a human autoimmune-like disorder characterized by chronic inflammation
of the small intestine induced by the ingestion of proline- and glutamine-rich wheat gluten and other
gluten-related proteins from rye and barley. Different symptoms and associated conditions can be
the hallmark of the disease [1]. The prevalence of the disease is approximately 1% in the western
world, although the majority of individuals have not been diagnosed [2]. The T-cell mediated damage
of the intestinal mucosa that causes malabsorption is histologically represented by villous atrophy,
crypt hyperplasia, and infiltration of lymphoid cells both in the epithelium and in the lamina propria.
Many patients have less overt intestinal changes and malabsorption may be limited to micronutrients.
CD is presently classified as symptomatic disease—which includes gastrointestinal and extraintestinal
manifestations–, and subclinical disease, which includes those subjects that do not have symptoms and
signs of overt clinical suspicion for the disease. Symptomatic CD can be further classified into classical
and atypical forms. Classical forms are those characterized by the typical picture of malabsorption
(i.e. diarrhoea and/or weight loss) whereas the term atypical refers to patients with minimal, transient,
or apparently unrelated symptoms. In recent years, the pattern of clinical presentation of adult CD has
changed and atypical presentation is now the most prevalent form of coeliac disease [1]. In addition,
CD subjects have an increased prevalence of autoimmune diseases, which may be found in 35% of
patients [3].
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A definite diagnosis of CD is based on histological changes, including intraepithelial lymphocytosis,
crypt hyperplasia, and varying degrees of villous atrophy, graded according to a classification system
proposed by Marsh and modified by Oberhuber (Marsh I-IIIc) [4].
The pathogenesis of the tissue damage in CD is related to genetic and environment factors
and is the consequence of complex mechanisms of activation belonged to both the acquired and the
innate branch of the immune system. Among innate immune cells, mast cells (MCs) were previously
associated with CD, but their role in the pathogenesis of the disease has been for long time unknown.
In this review we will briefly describe the main features of the immune response against gluten,
genetics as well as innate and acquired immune reactions. Then we will focus on the role of MC in the
complex scenario of the CD by: (i) describing the contribution of the MCs and of MC mediators in the
control of the intestinal functions; (ii) reviewing the past literature concerning the role of MCs in the
pathogenesis of coeliac disease; (iii) by presenting the most recent data that demonstrate the active role
of MC in the onset and progression of the CD. The aim of the review is to highlight the MC as a crucial
player in the CD.
2. Genetic and Immune Features of Coeliac Disease
CD has a strong genetic association, mainly with the genes coding for HLA-DQ2 and, to a lesser
extent, with the genes coding for HLA-DQ8. Gluten-reactive CD4+ T-cells have been isolated from the
small intestine of CD patients (but not from controls). These cells predominantly recognize peptides
derived by gluten in which glutamine residues at certain positions have been converted to glutamate
by the tissue transglutaminase 2 (TG2). This is the same enzyme that is the target of disease-specific
serum autoantibodies, which are detected in untreated CD patients [5].
Gluten peptides, once deamidated in situ by TG2, activate a T-cell specific response, which is
believed to play an essential role in the pathogenesis of CD. The anti-gluten immune response in CD is
further characterized by increased epithelial permeability [6] and increased influx of gluten peptides to
the lamina propria [7].
The genetic predisposition may favour the onset of CD from early childhood to old age. Although
HLA-DQ2 and HLA-DQ8 haplotypes predispose to CD, only a fraction of the carriers develops the
disease. The role of adaptive immunity in the pathogenesis of CD has been extensively studied.
Many different gluten peptides derived from gliadins and glutenins are able to stimulate CD4+ T-cells
of the small intestinal mucosa of CD patients [8,9]. Deamidation of these peptides by TG2 increases
their affinity for HLA-DQ2 [10,11] and results in strong activation of T-cell response dominated by
IFN-γ production [12,13] and additionally by IL-4, IL-5, IL-10, TNF and TGF-β [12]. Gluten-specific
T-cells also produce IL-21, but not IL-22 or IL-17 [13]. However, it has been reported that mucosal IL-17
is elevated in CD in later stages of mucosal inflammation, when villous atrophy has developed [14].
In wheat, gluten can be subdivided into gliadin and glutenin components. The gliadin proteins
are classified in α/β-, γ- andω-gliadins, whereas glutenin are classified into high (MW = 67,000–88,000)
and low molecular weight subunits (MW = 32,000–35,000).
Fifty different T-cell specific gluten epitopes both in native and deamidated forms has been
described [15], but the major gluten protein involved in CD is the α-gliadin isoform containing the
33-mer peptide (Figure 1), which is considered the most immunogenic fragment. The 33-mer peptide
is produced by digestion of α-gliadin proteins and it is resistant to enzymatic activity of gastric,
pancreatic and intestinal brush-border membrane enzymes [15]. The 33-mer fragment contains six
overlapping copies of three different HLA-DQ2-restricetd T-cell epitopes. Interestingly, this peptide can
activate T-cell by binding to HLA-DQ2 antigens directly on the surface of the antigen presenting cells
without needing further intracellular processing [16]. Therefore, gliadin can bypass the conventional
intracellular processing by undergoing extensive luminal and brush-border proteolysis and the resultant
antigenic peptides can be subjected to direct extracellular binding to surface HLA-DQ2.
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Figure 1. Amino acid sequence of the 33-mer and 25-mer fragments of the α-gliadin. Major 
immunogenic epitopes are indicated in red, while the sequence of the non-immunogenic fragment 
p31-43 is shown in blue. 
The role of other cell types has also been evaluated. CD8+ T-cells are particularly abundant in 
the coeliac intestinal mucosa and the massive infiltration particularly of the epithelium by these cells 
is one of the diagnostic hallmark of CD and is present even in mild forms of the disease [17]. These 
cells express activating natural killer receptors (NKRs) that recognize stress induced ligands and they 
can destroy distressed epithelial cells independently from their TCR specificity [18]. Gluten-reactive 
CD8+ T-cells can be isolated from intestinal biopsies of both treated and untreated CD patients [19]. 
However, these gluten-specific CD8+ T-cells in the coeliac mucosa are located in the lamina propria 
and not in the epithelium where tissue destruction is detected [20]. Therefore, the role of gluten-
specific CD8+ T-cell response is still to be fully elucidated. 
Although the role of adaptive immunity is well established, little is known about the early stages 
in which gluten starts the whole process, but it has been shown that an inflammatory response 
precedes the antigen-specific T-cell response [21]. Some data suggest that non-MHC genes and/or 
non-gluten environmental factors are involved in the development of the disease [22]. In this regard, 
the group of Lunardi and Puccetti has identified a disease-relevant auto-antigen peptide sharing 
homology with the VP-7 protein of rotavirus. Autoantibodies directed against VP-7 protein are 
detected in patients with active CD and cross-react with a desmoglein peptide and TLR4 peptide. It 
has been proposed that rotavirus, through a mechanism of molecular mimicry, may induce 
production of antibodies against the VP-7 protein that are self-reactive antibodies and are 
pathogenically relevant for their ability to alter the intestinal barrier integrity and to activate 
monocytes by engaging TLR4 [23]. 
Some other studies have focused the attention on the effect of gluten on innate immune response. 
In fact, beside its ability to induce immune responses, wheat contains several toxic peptides, which 
are capable of inducing mucosal damage. These epitopes have sequence homology with prolamins 
of other cereals, such as barley, rye and potentially although in minor quantity in oat [24]. Several 
non-immunogenic gluten peptides that stimulate innate immune response but not the adaptive 
immune responses have been investigated. The most studied toxic peptide is the derived a-gliadin 
p31-43 that is part of the longer peptide 25-mer (Figure 1) and is resistant to digestive enzymes in the 
gut [15]. In 2003, Maiuri and colleagues demonstrated that the fragment p31-43 is able to activate 
innate immune response by macrophages, monocytes and dendritic cells of the lamina propria, 
without stimulating CD4+ T-cells [25]. Both in vitro and in vivo experiments demonstrated that the 
effects of p31-43 peptide are dependent on the adapter Myd88 and the type I IFNs and involve the 
MAPK and NF-κB signalling cascades [26,27]. 
Interestingly, the innate response to p31-43 peptide was detected only in HLA-DQ2 positive CD 
patients, since it was not found in HLA-DQ2 positive non-coeliac controls [25]. Even more 
intriguingly, anti-IL-15 neutralizing antibodies could inhibit all the events related to innate immune 
activation, thus showing that this cytokine plays a key role as mediator of intestinal mucosa damage 
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B cells [28]. IL-15 supports the homeostasis between innate and adaptive immunity [29] and is involved
in the expansion and migration of intraepithelial lymphocytes (IELs) [30]. Concerning IELs, IL-15 can
lower the TCR threshold, making these cells able to kill targets that express IL-15 in a non-cognate yet
TCR-dependent way [31]. Moreover, IL15 may also prime towards a Th1 response [32], directing the
IFN-γ dominated gliadin T-cell activation and it has anti-apoptotic activities, protecting pathogenic
CD4+ T-cells from death [33].
3. Role of MCs in Coeliac Disease
3.1. Intestinal MCs Biology
MCs are tissue-residents belonging to the innate arm of the immune system. In the gastrointestinal
tract, they can be found in all layers but locate mainly in the lamina propria of the mucosa, where they
comprise 1–5% of mononuclear cells, and less in the submucosa (about 1% of all cells) [34].
MCs originate from circulating precursors that enter the intestinal mucosa through the
α4β7-MAdCAM-1 and α4β7-VCAM-1 interactions and under the influence of CXCR2 ligation [35,36].
Once in the intestinal mucosa, they acquire a unique mature phenotype, which consists in the expression
on the cell membrane of the IgE-specific high affinity receptor and of the proteases-containing granules
in the cytoplasm [37]. Historically, based on the protease content of their granules, MCs are classified
as MCs containing tryptase but little or no chymase (MCT) and MCs containing tryptase, chymase and
carboxypeptidase (MCTC). In the mucosa of the human small intestine, MCT amount to 98% of all
MCs while 77% of MCs resident in the sub-mucosa layer are MCTC [38,39].
MCs are endowed with a wide pattern of membrane-bound receptors (FcεRI, FcγR, TLRs,
protein G coupled receptors (GPCRs), chemokine and cytokine receptors) [40] and a great number of
costimulatory molecules, including members of the B7 family (ICOSL, PD-L1, and PD-L2) and of the
TNF/TNFR families (OX40L, CD153, Fas, 4-1BB, and glucocorticoid-induced TNFR), as shown in Table 1.
This plethora of receptors empowers the MC with the ability to respond to a multitude of stimuli
and to interact with different partners both from immune and non-immune cells populations [37].
Within the intestinal microenvironment, MCs are continuously exposed to different stimuli including
antigen-bounded Ig, pathogens, exogenous (food antigens) as well as endogenous molecules such
as neuropeptides, hormones, neurotransmitters and growth factors [37]. TLRs are fundamental
in sensing foreign and pathogenic molecules whereas protein G coupled receptors are implicated
with the recognition and binding of ligands of different origins ranging from antimicrobial peptides,
neuropeptides, lipids, and adenosine or complement fragments. The expression of several members of
both TLR [41] and GPCR families [42] confer to intestinal MCs the ability to sense every change in the
local microenvironment composition and to rapidly mount a specific response.
Table 1. Mast Cell (MC) receptors.
Receptor Family Members Ligands
FcR
FcεR FcεRI IgE
FcγR FcγRI, FcγRII, FcγRIII IgG
Toll like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7,TLR8, TLR9 Microbial PAMPs
G protein coupled
receptor MRGPRX2
Antimicrobial host defense peptides, neuropeptides,
major basic protein, substance P, vaso intestinal peptide
Adhesion molecules ICAM-1, VCAM, VLA4, Siglec6, Siglec7, Siglec8,SynCAM, N-cadherin, α2β1, α3β1, α4β1, α5β1, αVβ3 LFA-1, VLA-4, α4β1, sialic acid, fibronectin, collagen
Co-stimulatory molecules
TNF/TNFR family member CD40L, OX40L, 4-1BB, GITR, CD153, Fas, TRAIL-R CD40, OX40, 4-1BBL, GITR ligand, CD30, FasL, TRAIL
B7 family members CD28, ICOSL, PD-L1, PD-L2 CD80, CD86, ICOS, PD1, PD2
Nothch family members Notch1, Notch2 Jag1, Jag2, Delta1, Delta4
TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor.
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The triggering of MC receptors causes the cell activation and degranulation—i.e., the quick empty
of the granules content, followed by the neo-synthesis and secretion of many molecules with different
biological activities that influence all stages of the immune cell response with both pro-inflammatory
and immunosuppressive effect [43]. Furthermore, the same released mediators can also influence the
biology of the neighbouring cells, namely the intestinal epithelial cells and cells of the nervous system,
contributing to change of gut homeostasis (Table 2).
Table 2. Major MC-derived mediators and their effect on gastrointestinal (GI) mucosa.
Class Mediator Effect on GI Ref.
Pre-formed
Biogenic amines Histamine
Neuron excitation
Increased Cl− secretion
Increased intestinal motility
[44]
[45]
[46]
5-hydroxytryptamine Neuron excitation [47–49]
Proteases
Tryptase
TJ disruption
Increased intestinal permeability
Epithelial cell apoptosis
[50]
[50,51]
[52]
Chymase ECM degradationIncreased intestinal permeability
[53–55]
[55]
Proteoglicans Heparin Inhibition of cytokine and chemokines production [56–58]
Newly-synthesized
Lipid-derived PGD2 Increased electrolytic secretion [59]
LTC4, LTD4 Increased electrolytic secretion [59,60]
Cytokines IL-1, IL-6, IL-17, TNF-α TJ disruption [61–63]
Neuropeptides Vasoactive intestinalpeptide, NGF, SP Neuron excitation [64–66]
ECM, extracellular matrix; TJ, tight junctions.
The rapid emptying of the cytoplasmic granules, which contain preformed immunomodulatory
compounds such as histamine, serotonin, proteases, heparin, and TNF-α, has a strong effect on several
functions of the human intestine. Through the activation of the four histamine receptor subtypes
H1, H2; H3 and H4, histamine can induce both immunological response (H1-H4) as well as visceral
nociception (H1) [44], gastric acid secretion [45] and increased intestinal motility [46].
Serotonin, (5-hydroxytryptamine, 5-HT) regulates many functions of the small intestine by virtue
of its effect on neurones and intestinal cells and high levels of 5-HT are responsible of nausea, vomiting
and diarrhoea [47]. Indeed, the augmented spontaneous release of 5-HT was found to correlate with
increased MCs counts and with the severity of abdominal pain in inflammatory bowel disease [48].
Increased 5-HT content and enhanced 5-HT release from the upper small bowel have been identified in
CD subjects and have been correlated with dyspeptic symptoms in untreated patients [49] leading to
suppose a contribution of MC-derived 5-HT to the intestinal damage also in CD.
Tryptase activates a protease-activated receptor (PAR2) expressed on both the apical and basolateral
side of the intestinal epithelial cells causing calcium mobilization, actin redistribution and Zonulin
delocalisation [50,51] that consequently result in tight junctions’ disruption, cell apoptosis [52] and
increased intestinal permeability [50–52].
Similarly, once released MC chymase cleaves several substrates that are important for tissue
remodelling and extracellular matrix (ECM) degradation both directly and by activating ECM-degrading
proteases, including matrix metalloproteases [53–55]. This ultimately results in tissue damage and loss of
intestinal barrier integrity. Besides these pre-stored mediators with pronounced pro-inflammatory effect,
MCs are, together with basophils, the unique cells of the immune system that store and rapidly release
upon activation heparin. Apart from its anticoagulant activity, heparin plays an anti-inflammatory
role in the intestinal mucosa as it attenuates the production of pro-inflammatory cytokines such as IL-6
Int. J. Mol. Sci. 2019, 20, 3400 6 of 15
and TNF-α [56], inhibits neutrophil recruitment and activation [57] showing a protective effect against
intestinal mucosa damage.
Upon activation MCs release newly generated mediators, lipid derived (prostaglandin,
leukotrienes and platelet activating factor) and neo-synthetized (cytokines and growth factors)
molecules, that can have different effects on the gut homeostasis. In humans, PGD2 is the major
prostaglandin while LTC4 and LTB4 are the most prevalent leukotrienes secreted by activated MCs [58].
Albeit a direct role of these mediators on intestinal permeability in human is still debated, in animals
PGD2 and LTC4 were found to strongly induce intestinal secretion by direct actions on enteric
neurons [59]. Among the pro-inflammatory cytokines that MCs release, TNF-α, IFN-γ and IL-6 were
demonstrated to damage the intestinal epithelial barrier integrity by down-regulating the expression of
occludin [60], claudin 2 [61], claudin 3 [62] respectively. The consequent reorganization of the protein
architecture of the tight junctions alters the epithelial paracellular permeability.
Notably, the close proximity to sensory nerves in the intestinal mucosa permits the MCs to
tightly communicate with the cells of the nervous system. These MCs-nerves interactions are
bidirectional with neuronal activation that triggers the release of neuropeptides and neurotransmitters
that thereby can bind MC receptors and induce the secretion of soluble mediators that ultimately activate
neurons [63].Therefore, besides modulating innate and acquired immune response, intestinal MCs can
influence peristalsis, vascular and epithelial permeability, ion secretion, nociception, angiogenesis and
tissue repair, being crucially involved in the control of the gut homeostasis [64,65].
The ability of MCs to rapidly sense the modifications of the microenvironment and the ability to
adapt their response to the specific received trigger, results in different phenotypes of the activated MCs
described in different disorders of the intestine [66]. In the past, numerous studies have documented
an accumulation of MCs in the intestinal mucosa of patients affected by many gastrointestinal
diseases, including ulcerative colitis and inflammatory bowel disease (IBD), IBS, and in these contexts,
MCs resulted to be fundamental mediators of the pathology-associated inflammation [67,68]. However,
as stated by Theoharides and colleagues, the phenotype and the activation status of these MCs rather
than their absolute numbers in the inflamed intestinal mucosa is relevant for the development and
progression of the lesions [68].
In addition to these observations, it is worthy to note that MCs, in various tissues, express also
receptors for sex hormones that regulate their functionality and tissue distribution both in physiological
and pathological conditions [69]. Interestingly, sex hormones, estradiol, progesterone, and testosterone,
were found to induce MC histamine release in a dose- and gender dependent way [70]. In this
regard, a relationship between female hormones, MC-derived mediators and the development of
allergic and gastrointestinal inflammatory diseases has been hypothesized [71,72]. In particular,
oestrogen has been suggested to participate in pathogenesis of irritable bowel syndrome (IBS) [73].
Preliminary data on a newly described MC disorder, the mast cell activation syndrome, have shown
that 89% of patients were female and that the most common symptoms affect the gastrointestinal
tract, such as abdominal pain (94% of patients) and diarrhoea (67%). Interestingly, histologic and
immunohistochemical analysis performed on biopsies of patients undergone to endoscopy showed no
significant differences between patients and controls either in the number of intestinal MCs, or in the
distribution of MCs. This suggests that there are differences in MC activity among different subjects,
as well as between sex, with female MCs probably more prone to be activated. [74] Regarding CD,
several studies have shown that 60% of patients are female and it has been reported that women have
more severe disease than men. [75–77]. Thus, taken together these data suggest that MCs may sense
and react to changes in the hormonal milieu, especially oestrogens. This physiologic behaviour may
correspond in pathophysiology to a predisposition of women to develop gastrointestinal disorders
and to have more severe gastrointestinal symptoms and disease burden than men.
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3.2. Overview of Literature on MCs in CD
The first studies aiming at characterizing the role of intestinal mucosal MCs in CD date to 80s and
produced conflicting results [68–83].
Earliest histological investigations of MCs within the intestinal mucosa (Table 3) documented
a significantly decreased number of MCs in the lamina propria of CD patients as compared with
controls. In 1979, Kumar and colleagues reported values to be higher than normal in untreated CD
patients, remaining high after treatment with a gluten-free diet [78]. Similarly, in another report [79],
MC counts were found to be increased in untreated CD, but returning to normal level after gluten
withdrawal, while another study showed a positive correlation between increased values of infiltrating
mucosal MCs and the heights of the villi in untreated CD, values remaining lower than normal after
treatment [80]. Conversely, in the same years, both Dollberg [81] and Suranyi [82] demonstrated that
significantly lower numbers of accumulating MCs were found in intestinal biopsies from untreated
CD patients compared to healthy subjects, that return to the normal range in patients treated with
a gluten-free diet. Moreover, in a study performed in 1986 by the group of Horvath, the histological
analysis of the intestinal mucosa of 14 CD children showed a reduced number of MCs five hours after
challenge with gluten [83].
Table 3. MC implication in coeliac disease (CD).
Subjects MC or MC ProductIdentification Observation/Effect Reference
20 CD patients untreated and on
gluten-free diet Astra blu staining
MC numbers are higher than normal in intestinal
mucosa of untreated CD patients and remain high
after gluten-free diet
[70]
25 pediatric CD patients
10 pediatric CD patients on
gluten-free diet
Astra blu staining
Lower number of (granulated) MCs in intestinal
mucosa of untreated CD patients compared to
patients on gluten-free diet
Decrease in number of (granulated) MCs in patients
on gluten-free diet after receiving gluten
[73]
19 CD patients
11 CD patients on gluten-free diet
Astra blu/safranin pH 0.3
staining
Increase number of MCs in intestinal mucosa of
untreated CD patients returning to normal range
after gluten-free diet
[71]
47 pediatric CD patients
17 pediatric CD patients on
gluten-free diet
Iron diamine staining
Positive correlation between number of MCs and
villous height
Increased number of (granulated) MCs in patients
under diet regimen
[72]
20 pediatric CD patients untreated
and on gluten-free diet Toluidine blu staining
During the untreated phase of the disease the MC
number in the intestinal mucosa is depressed.
On a gluten-free diet the number of MCs rises
[74]
14 children with treated CD disease Toluidine blu staining Reduced number of intestinal MCs 5h after singlechallenge with gluten [75]
10 adult CD patients Histamine releasedetection
Gliadin perfusion of closed jejunal segment induces
a twofold histamine secretion in CD patients
compared to control
[76]
10 adult CD patients on
gluten-free diet Toluidine blu staining
Rapid reduction (1h) of MC numbers in the rectal
mucosa of CD patiets after instillation of gluten
solution into the rectum
[77]
37 adult CD patients on
gluten-free diet Toluidine blu staining
Reduced numbers of (granulated) MCs in the oral
submucosa of CD patients after injection of gliadin
solution into the buccal submucosa
[78]
20 Non-coeliac gluten sensitivity
(NCGS) patients
16 CD patients (Marsh 1–2)
CD117 staining CD117+ cells are higher in jeunal biopsies of NCGSand CD patients compared to control [79]
10 Marsh1 CD patients
9 Marsh2 CD patients
9 Marsh3 CD patients
Tryptase staining
Increased numbers of trptase+ cells in intestinal
mucosa of Marsh 2 and Marsh 3 compare to Marsh 1
CD patients and controls
The disease worsening associates with the
acquisition of a pro-inflammatory phenotype of MCs
[80]
These discrepancies were probably caused by errors in the analysis of intestinal biopsy specimens
due to inappropriate employed methodology. Indeed, these studies were mainly retrospective analysis
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of tissues, which had been processed for diagnostic purposes, and probably they were not handled
properly for the identification of MCs. Thus, these earlier conflicting observations were attributable
to different fixative-associated blocking agents and staining procedures, which impair the adequate
histochemical visualization of the MC granules.
However, in 1989, a first functional study documented a potential active role of MCs in the
mechanism of gluten-induced jejunal damage [84]. In the paper by Lavö, the authors observed that
in vitro gluten perfusion of small intestinal biopsies from CD patients induced a two-fold increase of
histamine secretion within 40 minutes, but did not influence the secretion rates of histamine in biopsies
from healthy controls [84].
Related experiments aimed to investigate the primary response of immune cells and MCs to local
gluten challenge were performed by other groups and gave similar results. In their studies on rectal
mucosa, Loft and colleagues demonstrated a strong reduction in the number of toluidine-blue stained
MCs in rectal biopsies of CD patients exposed to gluten for 24 hours and ascribed this reduction in
granulated MCs to the empty of granules as consequence of the degranulation response to gliadin [85].
Similarly, a decrease in degranulated MCs was observed in the oral mucosa of CD patients after gluten
challenge. In fact, despite the comparable numbers of MCs in the lamina propria of the oral mucosa
of CD patients and controls before gliadin challenge, after gliadin injection into the oral submucosa
a significant reduction in the total numbers of MCs was found in CD patients but not in controls [86].
These were the first evidences of a direct response of MCs to gluten challenge. Nevertheless,
the difficulties in the identification and isolation of intestinal MCs have precluded inferring clues about
the role of MCs in the CD pathogenesis and pathophysiology for long time (Table 1). Indeed, only in
2017 new studies on the role of MCs in CD were published.
In a recent work of Losurdo and colleagues, 20 subjects with non-coeliac gluten sensitivity
(NCGS) and 16 CD patients (classified as Marsh 1 and Marsh 2) were enrolled to investigate the
specific expression of markers of adaptive and innate immunity activation in the course of the disease.
The authors specifically identified intestinal MCs by CD117 staining (i.e., the receptor for SCF that is
constitutively expressed by mature MCs) and demonstrated that MCs accumulate in the intestinal
mucosa of both NCGS and CD patients [87]. In the same year, by analysing and scoring the intestinal
biopsies of CD patients for immune cells infiltration (including B, T-cells as well as macrophages and
MCs) according to Marsh classification, the histological damage progression in CD has been associated
with the density of infiltrating MCs (Figure 2) and their ability to bind the non-immunogenic gliadin
p31-43 peptide and to release inflammatory mediators in response to p31-43 [88].
3.3. MC as a New Player in CD
In the study carried out in 2017 on human MC lines and primary cultures of intestinal MCs,
we proved a direct role of these cells in onset of the immune response to gliadin, and in keeping disease
progression [88]. We observed that both LAD2 human MCs and intestinal mucosal MCs selectively
react to the treatment with the non-immunogenic p31-43 fragment of the gliadin but not to other gluten
proteins, or to gliadin immunogenic peptides. The p31-43 fragment is the only one capable of inducing
the release of histamine and specific pro-inflammatory cytokines through the generation of reactive
oxygen species and the activation of the transcription factor NF-κB. By using primary cultures of MCs
obtained from mice genetically deficient of the Myd-88 adaptive molecule, we also showed that p31-43
requires the TLR pathway to induce MC activation [88].
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Moreover, different in vitro responsiveness to p31-43 peptide stimulation was observed: intestinal
MCs isolated from healthy subjects responded less (in term of histamine release) than MCs isolated
from CD subjects, and the magnitude of MC response is directly associated to the severity of intestinal
lesi ns from which they stem. Indeed, MCs isolat d from the intestinal mucosa of CD pati nts class fied
as Ma sh 3 release more histamine in response to p31-43 peptide than MCs isolated from Marsh 1
patients [88].
Among all the cells infiltrating the i testinal mucosa of CD subjects, we have als shown that
MCs are the only cells that accumul te proportionally to the w rsening of the extent of tissue d mage
(Figure 2). Mor over, such numeric l increase is accompanied by a phenotypic change of intestin l
MCs, which progressively become a cellular source of TNF-, IL-6 and IL-17 [88].
Thus, if the release by MCs of histamine and inflammatory mediators following the trigger
with gliadin p31-43 peptide could b accountable f r the increase of leukocytes and of PMNs
in the early stage of the disease [89] (Figure 3B), th sub equent increase in the production of
pro-inflammatory cytokine (IL-6 and IL-17 mainly) by intestinal MCs will be accoun able for T- and
B-cell activation (Figure 3C). Inde d, the cytokine milieu that MCs generate in response t gliadin
activation contributes to intraepithelial T-cell activation and Th17 cell expansion and supports th
skewing towards M1 phenotype of macrophages that will sustain T-cell response via presentation of
immunogenic gluten peptides. Moreover, gliadin-activated MCs can also influence—in a T-independent
way—th proliferation and differentiation of B cells into IgA-p oducing plasma cells owing to the
constitutive exp ssion of CD40L and the secretion of IL-6 [90] in response to p31-43 peptide challenge.
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4. Conclusions and Future Perspectives
Even though finding a moderate correlation between a cytokine and the worsening of the disease
is not possible, it is worth to note that during CD progression MCs increase in number and contribute
to define a pro-inflammatory microenvironment. Considering that MCs are at the forefront in the
interaction with the environment due to their privileged position within the mucosal tissue, the ability
of MCs to respond to gliadin peptides accounts firstly for a direct role of MCs in the onset of CD.
The ability of MCs, as monocytes and macrophages, to directly react against gluten challenge strongly
supports the contribution of the innate immune system in initiating the immune response to gluten.
Secondly, the observed changes in type and amounts of soluble mediators released by MCs during
the progression of the disease indicate that the behaviour of MCs is not fixed and varies in response
to microenvironment modifications. The association of different phenotypes of MCs with different
histological degrees of intestinal lesions suggests that these modifications can be ascribed to the MCs
change in cytokine profile or activity. In other words, the characterization of the phenotype of intestinal
MCs could represent a “snapshot” of the status of the CD progression.
To date MCs cannot be taken as a truly marker of CD and further work is needed to better
understand the role of these type of cells in the different setting of CD (i.e., refractory CD, in the same
patient before and after gluten free diet, etc.). However, the presence of MCs from the beginning of
the disease as well as their modifications over time are in favor of a plastic and active role of these
cells that could be modulated by external triggers. Medications able to control MC activity are not
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jet available but the evidence that MCs can be triggered by diverse stimuli should direct researchers
toward the identification of specific molecules to tune MCs.
In conclusion, it can be assumed that MCs represent one of the main players of the intestinal
damage in the onset of CD. Hence, the pathogenesis of CD disease should be revised and the
contribution of MCs in the onset and progression of the disease should be considered in the planning
of new therapeutic approaches.
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